BSE filing, NSE: SHILPAMED. Summary written from the filing by ALFA Finder's alert engine.
Shilpa Medicare Ltd: key numbers
- Share price
- ₹932.80
- Market cap
- ₹18,244 Cr
- Revenue (annual)
- ₹1,539 Cr
- Net profit (annual)
- ₹243.3 Cr
- P/E (TTM)
- 61.4×Sector 46.1×
- Promoter holding
- 40.13%+0.00% QoQ
- FII holding
- 12.11%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shilpa Medicare Ltd
All →Shilpa Medicare Board Meeting Date
Shilpa Medicare's board meeting is scheduled for 5 November 2026 to approve Q2 and H1 unaudited financial results. The trading window remains closed until 7 November 2026.
Shilpa Medicare Business Update
Shilpa Medicare Limited’s Unit 4 in Jadcherla received GMP certification from AGES, Austria, following a successful inspection. This milestone enables operations for European and global markets.
Shilpa Medicare Other Announcement
Shilpa Medicare Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Shilpa Medicare Other Announcement
Shilpa Medicare Ltd KMP Alpesh Maheshkumar Dalal sold 4,000 equity shares via market sale. The transaction was valued at Rs.0.42 Crore and executed on the NSE.
- Value
- ₹0.42 Cr
Shilpa Medicare Share Pledge
The company's promoters reported the release of encumbrance on 30,00,000 equity shares held by them. This reduction in pledged shares signals a change in promoter leverage.
Shilpa Medicare Other Announcement
Shilpa Medicare received a 'Crisil ESG 59' rating from CRISIL ESG Ratings for FY2026. This is a routine regulatory disclosure under Regulation 30 with no financial implications.
Other other announcement announcements
All →Milky Mist Dairy Food Other Announcement
Milky Mist's board appointed B Chandra & Associates as Secretarial Auditors for FY 2026-27 to 2030-31. Shareholder approval is pending at the ensuing AGM.
- Execution
- FY 2026-27 to FY 2030-31 (five years)
Mahamaya Lifesciences Other Announcement
Mahamaya Lifesciences Ltd, an SME-platform listed company, confirms non-applicability of Corporate Governance under Regulation 27(2) for the quarter ended 30 September 2026. A Company Secretary certificate is enclosed.
Wipro Other Announcement
Wipro disclosed a designated person's 34,200-share ADR sale worth about ₹0.67 Crore on 28 October 2026. The sale followed RSU exercise, leaving 60,266 securities held.
- Value
- ₹0.67 Cr
OK Play India Other Announcement
OK Play India filed its quarterly shareholding pattern for the quarter ended September 2026. It shows category holdings only, with no transaction.
Spice Islands Industries Other Announcement
Spice Islands Industries filed a Reg 32 statement reporting no deviation in preferential issue fund utilization for Q3 FY27. The ₹8.70 Crore raise is fully deployed.
Setubandhan Infrastructure Other Announcement
RP informs exchanges that Setubandhan Infrastructure cannot file quarterly compliance documents due to depository fee non-payment. The company remains under CIRP with a pending NCLAT appeal.